President Trump’s latest attempt at implementing International Reference Pricing- based (IRP-) methodology to regulate drug prices in the US has the broadest and strictest scope.
Anaïs Frappé
Advertisement
Articles by Anaïs Frappé
Cancer patients’ journeys are complex and the benefit of a drug goes well beyond survival, even in cases of incurable and/or metastatic cancer.
Advertisement
Latest Updated Articles
Re-Thinking Oncology HTAs: the (Growing) Role of Non-OS EndpointsPublished: June 23rd 2025 | Updated:
Advertisement
Advertisement
Trending on PharmExec
1
Excellergy Announces Launch with $70 Million Series A Funding Aiming to Advance Pipeline of Trifunctional Effector Cell Response Inhibitors
2
How are the Drug Pricing Negotiations Impacting Pharma's Relationship with DC?
3
Pharma Companies Shift Towards Direct-To-Consumer Sales in US Amidst Tariff and Pricing Turmoil
4
Policy Whiplash in Pharma: Navigating Volatility with Strategic Clarity
5
